EcoDrugPlus

Sirtuin 1

Ensembl ID : ENSTGUG00000003480
Gene Symbol: SIRT1
1 Cross references
157 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Smoothened, Frizzled Class Receptor

Ensembl ID : ENSTGUG00000001868
Gene Symbol: SMO
3 Cross references
204 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Sodium Channel Epithelial 1 Subunit Alpha

Ensembl ID : ENSTGUG00000013342
Gene Symbol: SCNN1A
1 Cross references
153 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Sodium Channel Epithelial 1 Subunit Beta

Ensembl ID : ENSTGUG00000005936
Gene Symbol: SCNN1B
3 Cross references
151 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Sodium Channel Epithelial 1 Subunit Gamma

Ensembl ID : ENSTGUG00000028767
Gene Symbol: SCNN1G
3 Cross references
155 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Sodium Channel Protein Type 1 Subunit Alpha

Ensembl ID : ENSTGUG00000007356
Gene Symbol: LOC100224567
2 Cross references
233 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Sodium Channel Protein Type 4 Subunit Alpha-Like

Ensembl ID : ENSTGUG00000000476
Gene Symbol: LOC100220381
2 Cross references
277 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Sodium Channel Protein Type 8 Subunit Alpha

Ensembl ID : ENSTGUG00000003307
Gene Symbol: LOC115491370
2 Cross references
273 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Sodium Voltage-Gated Channel Alpha Subunit 3

Ensembl ID : ENSTGUG00000007034
Gene Symbol: SCN3A
3 Cross references
135 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Sodium Voltage-Gated Channel Alpha Subunit 4

Ensembl ID : ENSTGUG00000003230
Gene Symbol: SCN4A
3 Cross references
193 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Solute Carrier Family 10 Member 2

Ensembl ID : ENSTGUG00000010806
Gene Symbol: SLC10A2
3 Cross references
214 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Solute Carrier Family 18 Member A2

Ensembl ID : ENSTGUG00000011058
Gene Symbol: SLC18A2
3 Cross references
221 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).